RxDoctor Payments Data

Ruben Gil, MD

Cardiovascular Disease · Miami, FLNPI 1760411003

Payments from drug & device makers

$9,393in general payments, 2019–2025

Across 267 payments — averaging $35.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • Esperion Therapeutics, Inc.$1K
  • AstraZeneca$876
  • Abbott$734
  • Novartis$670
  • Amarin Pharma, Inc.$517
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$9,05196%
  • Education$3414%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,393 in reported general payments places this provider in the 70th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$40,067
Medicare patients
154
Services billed
432

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab441$320,732
XareltoRivaroxaban54$57,847
EliquisApixaban72$56,568
EntrestoSacubitril/Valsartan44$44,281
VascepaIcosapent Ethyl81$43,809
Praluent PenAlirocumab48$32,827
NexletolBempedoic Acid38$18,002
FarxigaDapagliflozin Propanediol14$9,972
Repatha PushtronexEvolocumab13$8,011
EdarbiAzilsartan Medoxomil11$3,306
Metoprolol Succinate242$2,078
Ezetimibe150$1,968
Omega-3 Acid Ethyl Esters18$1,687
Atorvastatin Calcium246$1,551
Ranolazine ErRanolazine22$1,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$385$57,84754 claims
PfizerEliquis$38$56,56872 claims
NovartisEntresto$670$44,28144 claims
Esperion Therapeutics, Inc.Nexletol$1,265$18,00238 claims
AstraZenecaFarxiga$876$9,97214 claims
Arbor Pharmaceuticals, Inc.Edarbi$28$3,30611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →